Clinical trialNo phase (not a drug trial)Unknown
99mTc-CNDG Injection in the Diagnosis of Malignant Tumors
A Prospective Study to Explore the Performance and Efficacy of 99mTc-CNDG Injection in Malignant Tumors
- Outcome
- Outcome unknown
- Phase
- No phase (not a drug trial)
- Status
- Unknown
- Study type
- Interventional
- Start
- 11 August 2023
- Listed end
- 31 December 2025
- Enrollment
- 100 participants
- Sites
- 1
- Primary outcomes
- Uptake value of 99mTc-CNDG in malignant tumors; Lesions detected by 99mTc-CNDG SPECT/CT; Compared with 18F-FDG PET/CT or CECT
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 11 September 2023
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Currently, 18F-fluorodeoxyglucose (18F-FDG) is the most widely used tumor imaging agent in clinical practice. However, the production of 18F requires accelerators and is associated with relatively high diagnostic costs, which to some extent limits its widespread clinical application. In comparison to Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT) devices are more abundant and offer lower diagnostic expenses. With the utilization of Cadmium Zinc Telluride (CZT) crystals in SPECT and advancements in image reconstruction techniques, the resolution and sensitivity of SPECT is continually improving. Therefore, the development of a simplified and cost-effective novel SPECT tumor imaging agent holds significant practical significance. This study involved the design and synthesis of a glucose-derived ligand with a linker containing seven methylene units and an isonitrile group (CN7DG). The CN7DG ligand was labeled with 99mTc to prepare a more lipophilic 99mTc-CN7DG complex, aiming to investigate a novel SPECT imaging agent for tumor imaging.